<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11861705</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.449</article-id><article-id pub-id-type="other">EPP0260</article-id><article-id pub-id-type="pii">S0924933824004498</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Cardiovascular risk associated with chronic treatment of paliperidone, olanzapine, risperidone and aripiprazole</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Montejo</surname><given-names>A. L.</given-names></name><xref rid="aff0964" ref-type="aff">
<sup>1</sup></xref><xref rid="cor0310" ref-type="corresp">
<sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bermejo</surname><given-names>C.</given-names></name><xref rid="aff0965" ref-type="aff">
<sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mat&#x000ed;as</surname><given-names>J.</given-names></name><xref rid="aff0966" ref-type="aff">
<sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mart&#x000ed;n</surname><given-names>T.</given-names></name><xref rid="aff0966" ref-type="aff">
<sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mat&#x000ed;as-Polo</surname><given-names>J.</given-names></name><xref rid="aff0966" ref-type="aff">
<sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Santana</surname><given-names>Y.</given-names></name><xref rid="aff0966" ref-type="aff">
<sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>L&#x000f3;pez-L&#x000f3;pez</surname><given-names>J.</given-names></name><xref rid="aff0966" ref-type="aff">
<sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>de Alarc&#x000f3;n</surname><given-names>R.</given-names></name><xref rid="aff0964" ref-type="aff">
<sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Acosta</surname><given-names>J. M.</given-names></name><xref rid="aff0965" ref-type="aff">
<sup>2</sup></xref></contrib></contrib-group><aff id="aff0964">
<sup>1</sup>Psychiatry, <institution>University of Salamanca</institution>. <city>IBSAL</city>
</aff><aff id="aff0965">
<sup>2</sup><institution>Neurociencias</institution>, <city>IBSAL</city>
</aff><aff id="aff0966">
<sup>3</sup>Psychiatry, <institution>Complejo Asistencial Salamanca</institution>. IBSAL, <city>Salamanca</city>, <country>Spain</country>
</aff><author-notes><corresp id="cor0310">
<label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="424">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S209</fpage><lpage>S209</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824004498a.pdf"/><abstract><sec id="sec1861"><title>Introduction</title><p>Weight gain, QT interval prolongation, and dyslipidemias associated with the chronic use of some antipsychotic medications can explain a higher prevalence of cardiovascular risk in these psychiatric population. The D&#x02019;Agostino Index include some factors such as age, total cholesterol, high-density lipoproteins, systolic blood pressure increased, antihypertensive treatment, smoking, and diabetes, to estimate an individual&#x02019;s risk (low, moderate or severe) of developing a cardiovascular event through a period of 10 years or throughout the patient&#x02019;s lifetime.</p></sec><sec id="sec1862"><title>Objectives</title><p>To compare the degree of cardiovascular risk using the D&#x02019;Agostino Index, among different antipsychotic medications.</p></sec><sec id="sec1863"><title>Methods</title><p>An estimation of cardiovascular risk (low, moderate, or high) was performed with the D&#x000b4;Agostino index in a sample of 144 patients (82 men and 62 women) mean age 45,2 +/- 10.13. All patients were treated for at least one year at a therapeutic dose and adhered to their treatment regimen correctly. Subjects with some relevant pre-existing unstable heart disease were excluded. All patients previously provided informed consent and were of legal age. Clinical data on medical history, concomitant medications, and risk factors were collected. A completed physical exam, waist circumference, lab sample, a lifestyle scale, and an evaluation of vital signs in accordance with European Society of Hypertension were evaluated. Statistical analysis was carried out using the statistical software SPSS version 26.0. A significance level &#x003b1;=0.05 was considered throughout the study.</p></sec><sec id="sec1864"><title>Results</title><p>The four most consumed antipsychotics were risperidone 9.72% (n=14), paliperidone 25.7% (n=37), olanzapine 14.6% (n=21), and aripiprazole 34.7% (n=50). Descriptively, it was observed that the drugs most associated with moderate or high risks were paliperidone (37.8%) and olanzapine (33.3%), risperidone (28.6 %). Aripiprazol (22%) was the less associated compound with moderate/high cardiovascular risk.</p></sec><sec id="sec1865"><title>Conclusions</title><p>Subjects treated with olanzapine and paliperidone showed a higher association with cardiovascular risk. Predicting cardiovascular risk could provide individual benefits by enabling lifestyle modifications, pharmacological treatment changes, or closer monitoring to reduce cardiovascular risk.</p></sec><sec id="sec1866"><title>Disclosure of Interest</title><p>A. Montejo Grant / Research support from: This study has been funded by the Instituto de Salud Carlos III (ISCIII) through the project PI19/1596 and co-funded by the European Union., C. Bermejo: None Declared, J. Mat&#x000ed;as: None Declared, T. Mart&#x000ed;n: None Declared, J. Mat&#x000ed;as-Polo: None Declared, Y. Santana: None Declared, J. L&#x000f3;pez-L&#x000f3;pez: None Declared, R. de Alarc&#x000f3;n: None Declared, J. Acosta: None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>